Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood and Marrow Transplantation Volume 19, Issue 6, Pages 860-866 (June 2013) DOI: 10.1016/j.bbmt.2013.01.003 Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 1 Neutrophil engraftment for 12 patients who received ex vivo, PGE2-treated double UCBT (PGE2) and 53 who received PGE2-untreated double UCBT (control). Death is the competing event of neutrophil engraftment. Biology of Blood and Marrow Transplantation 2013 19, 860-866DOI: (10.1016/j.bbmt.2013.01.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 2 Cumulative incidence of chronic GVHD with and without excluding chronic GVHD incidences that occurred after the taper of immunosuppression among 176 patients who underwent matched unrelated RIC HSCT. Biology of Blood and Marrow Transplantation 2013 19, 860-866DOI: (10.1016/j.bbmt.2013.01.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions
Figure 3 Cumulative incidence of relapse with different donor types among 1,715 patients from the International Bone Marrow Transplantation Registry between 1985 and 1991. (Adapted and reprinted with permission from Klein and Andersen [7].) Biology of Blood and Marrow Transplantation 2013 19, 860-866DOI: (10.1016/j.bbmt.2013.01.003) Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions